A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer

(2012) Massimo Cristofanilli et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors

(2012) Maja J. A. de Jonge et al.   INVESTIGATIONAL NEW DRUGS

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

New Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines for Advanced Non–Small Cell Lung Cancer: Comparison With Original RECIST and Impact on Assessment of Tumor Response to Targeted Therapy

(2010) Mizuki Nishino et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy Compared With Pazopanib Plus Lapatinib Combination Therapy in Patients With Advanced and Recurrent Cervical Cancer

(2010) Bradley J. Monk et al.   JOURNAL OF CLINICAL ONCOLOGY

Application of COLD-PCR for improved detection of KRAS mutations in clinical samples

(2009) Zhuang Zuo et al.   MODERN PATHOLOGY

Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines

(2009) K A Olaussen et al.   ONCOGENE

Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Cancer Cells

(2008) R. Bianco et al.   CLINICAL CANCER RESEARCH

Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity

(2008) Nilofer S. Azad et al.   JOURNAL OF CLINICAL ONCOLOGY